Haverford Trust Co Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Haverford Trust Co cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,615 shares of the biopharmaceutical company’s stock after selling 207 shares during the period. Haverford Trust Co’s holdings in Gilead Sciences were worth $974,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in GILD. Koshinski Asset Management Inc. purchased a new stake in Gilead Sciences during the first quarter worth $217,000. TD Asset Management Inc lifted its holdings in Gilead Sciences by 2.5% during the first quarter. TD Asset Management Inc now owns 1,055,180 shares of the biopharmaceutical company’s stock valued at $77,292,000 after purchasing an additional 25,523 shares in the last quarter. Trillium Asset Management LLC lifted its holdings in Gilead Sciences by 25.0% during the first quarter. Trillium Asset Management LLC now owns 164,129 shares of the biopharmaceutical company’s stock valued at $12,022,000 after purchasing an additional 32,792 shares in the last quarter. Dorsey & Whitney Trust CO LLC lifted its holdings in Gilead Sciences by 16.1% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 12,613 shares of the biopharmaceutical company’s stock valued at $924,000 after purchasing an additional 1,746 shares in the last quarter. Finally, GM Advisory Group LLC purchased a new position in Gilead Sciences during the first quarter valued at $263,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 56,947 shares of company stock valued at $4,968,674 over the last 90 days. 0.16% of the stock is owned by company insiders.

Gilead Sciences Trading Down 1.8 %

Shares of GILD stock opened at $92.63 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.11 and a quick ratio of 0.82. The firm has a market cap of $115.32 billion, a PE ratio of 1,029.22, a price-to-earnings-growth ratio of 2.91 and a beta of 0.17. The company has a 50-day moving average of $85.95 and a two-hundred day moving average of $75.57. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.29 earnings per share. On average, analysts predict that Gilead Sciences, Inc. will post 4.39 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.33%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on GILD shares. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $74.00 to $96.00 in a report on Monday, October 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Cantor Fitzgerald increased their price objective on shares of Gilead Sciences from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Finally, Robert W. Baird increased their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, ten have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.50.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.